SkinMedica, Inc. Announces Appointment of Joe Willis to Vice President, Sales and Marketing

Published: Jan 04, 2011

CARLSBAD, Calif., Jan. 4, 2011 /PRNewswire/ -- SkinMedica, the fastest-growing professional skin care company in the United States, announced today the appointment of Joe Willis to Vice President, Sales and Marketing. He will report to Ted Schwarz, President of SkinMedica, and will be responsible for all commercial aspects of the Company's business.


"Joe has an outstanding track record of success in dermatology sales and marketing," commented Ted Schwarz, President of SkinMedica. "His proven ability to build and lead cross-functional teams, develop and launch new products, and partner with aesthetics practices to drive growth aligns perfectly with our approach to addressing the aesthetics skin care market."

Mr. Willis has dedicated more than 20 years of his career to the specialty of dermatology, in both the medical and aesthetics fields, most recently as General Manager of Ortho Dermatologics, a Johnson & Johnson company. Previously, he was Vice President of Marketing and Business Development at Coria, where he delivered market leading sales growth. Prior to that, Mr. Willis served as Director of Marketing at Galderma where he and Mr. Schwarz worked together in marketing and sales leadership.

"I am very excited to join such a vibrant, focused, growing organization with a world-class product offering and an excellent sales and marketing team," said Mr. Willis. "I've been impressed by SkinMedica's dedication to science and clinically proven results, and am confident in our path to market leadership."

About SkinMedica, Inc.

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The Company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum and hallmark TNS Recovery Complex®. The formulations in the Company's clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica's prescription products include VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women and EpiQuin® Micro Cream (4% hydroquinone) for hyperpigmentation, or "brown spots" that commonly result from aging, inflammation or sun exposure.

SkinMedica is based in Carlsbad, California. For more information, visit:

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.

SOURCE SkinMedica, Inc.

Back to news